FDA approves second drug for a site-agnostic indication; larotrectinib was tested across 17 cancer types

Iowa’s Mark Burkard sees a role for data science in bringing clinical trials to rural clinics
The state has the second highest (and rising) cancer rates in the U.S.

A curious piece of paper hangs in a frame outside the director’s office at University of Iowa Holden Comprehensive Cancer Center on the second floor of the General Hospital.

November 01, 2024

Vol.50 No.41

By Paul Goldberg

Regulatory News

At his 25-year “anniversary party,” Pazdur invites Califf and past FDA commissioners to talk about political interference

FDA’s cancer czar Richard Pazdur had a “silver anniversary” at the agency recently. So, he invited some guests—the commissioners he had reported to under the Democratic and Republican administrations.

November 01, 2024

Vol.50 No.41

By Claire Marie Porter

Regulatory News

FDA extends shelf-life for IV fluids in shortage after Hurricane Helene

More than a month has passed since Hurricane Helene took out Baxter North Cove plant, which manufactured 1.5 million IV fluid bags per day, supplying 60% of the intravenous solutions nationwide.

November 01, 2024

Vol.50 No.41

By Claire Marie Porter

Clinical Trials & Tribulations

Addressing high cancer mortality in Native Hawaiian and Pacific Islander populations
A call for equity in cancer research

After reading “Breast Cancer Mortality Continues Three-Decade Decline, but Steeper Increases for Women Under 50 & AAPI Women of All Ages,” it is evident that while overall progress is being made in the fight against cancer, concerning disparities remain—particularly within the Native Hawaiian and Pacific Islander (NHPI) communities.

“Less Radical” podcast: Resistance to change, a data scandal

“Less Radical” is the story of Bernie Fisher, the surgeon-scientist who not only revolutionized breast cancer treatment, but also fundamentally changed the way we understand all cancers.

November 01, 2024

Vol.50 No.41

In Brief

UChicago receives $75M from AbbVie Foundation for construction of the cancer care and research pavilion

UChicago Medicine received a $75 million donation from the AbbVie Foundation, a nonprofit focused on advancing health equity, to help fund the construction of the new cancer care and research pavilion.

November 01, 2024

Vol.50 No.41

FDA approves second drug for a site-agnostic indication;

larotrectinib was tested across 17 cancer types

YOU MAY BE INTERESTED IN

Iowa’s Mark Burkard sees a role for data science in bringing clinical trials to rural clinics
The state has the second highest (and rising) cancer rates in the U.S.

At his 25-year “anniversary party,” Pazdur invites Califf and past FDA commissioners to talk about political interference

FDA extends shelf-life for IV fluids in shortage after Hurricane Helene

Addressing high cancer mortality in Native Hawaiian and Pacific Islander populations
A call for equity in cancer research

“Less Radical” podcast: Resistance to change, a data scandal

UChicago receives $75M from AbbVie Foundation for construction of the cancer care and research pavilion

Renew today!

Subscriber content

Login

FDA approves second drug for a site-agnostic indication;

larotrectinib was tested across 17 cancer types

YOU MAY BE INTERESTED IN

Iowa’s Mark Burkard sees a role for data science in bringing clinical trials to rural clinicsThe state has the second highest (and rising) cancer rates in the U.S.

At his 25-year “anniversary party,” Pazdur invites Califf and past FDA commissioners to talk about political interference

FDA extends shelf-life for IV fluids in shortage after Hurricane Helene

Addressing high cancer mortality in Native Hawaiian and Pacific Islander populationsA call for equity in cancer research

“Less Radical” podcast: Resistance to change, a data scandal

UChicago receives $75M from AbbVie Foundation for construction of the cancer care and research pavilion

Login

Iowa’s Mark Burkard sees a role for data science in bringing clinical trials to rural clinics
The state has the second highest (and rising) cancer rates in the U.S.

Addressing high cancer mortality in Native Hawaiian and Pacific Islander populations
A call for equity in cancer research